Carl Zeiss Meditec is the worldwide leading provider of system solutions to diagnose and treat eye disorders. The Cirrus HD-OCT high definition retinal scanner uses spectral domain technology to capture 3D line scans of the retina. The high resolution images allow better visualization and understanding of disease pathogens, assisting the examination of patients with retinal degenerations, uncommon macular disorders and glaucoma.
In order to accelerate the product’s introduction to market the Carl Zeiss Meditec development team relied upon CoCreate as part of a complete 3D virtual prototyping process that allowed the team to eliminate one cycle of physical prototypes. As a result, the company introduced the Cirrus HD-OCT to market five months ahead of a typical development schedule. Carl Zeiss Meditec used CoCreate Modeling and its associativity with finite element modeling software packages to virtually prototype and optimize the thermally sensitive mounts for the optical components.
As is typical when developing new technology, the product development team had to adapt to evolving requirements. By using an explicit approach to 3D product development, Carl Zeiss Meditec was able to quickly and easily adapt the original design. Additionally, the company automated its data management processes by using CoCreate Model Manager to extend the use of the 3D product data to downstream departments, ensuring that its manufacturing, procurement and supply chain departments had controlled access to the most up-to-date product design data.
“The flexibility of CoCreate 3D modeling allowed the engineers to be creative, which enabled us to develop a novel and extremely compact instrument in a shorter than usual schedule” said Chris Baker, director of mechanical engineering, Carl Zeiss Meditec. “CoCreate Model Manager made it easy to access and reuse existing components on this project while ensuring that engineers always had the latest part revisions during design.”
“Many customers like Carl Zeiss Meditec face short lead times and come from fast-paced industries where the ability to respond to unpredictable product and requirement changes is critical to their success,” said Martin Neumueller, director, product management, PTC. “The explicit modeling approach provided by CoCreate allows product development teams to quickly create and modify 3D product designs and provides flexibility to make unexpected and radical changes to a product design until late in the development process. This capability was critical to the success achieved by Carl Zeiss Meditec.”
About Carl Zeiss Meditec
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world’s leading medical technology companies. This market position is based on over 160 years of experience in optical innovation. The company has two primary areas of activity. In the field of ophthalmology, Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. Product innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyzer, the Stratus OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery. For more information on Carl Zeiss Meditec, please visit http://www.meditec.zeiss.com/
PTC (Nasdaq: PMTC) provides discrete manufacturers with software and services to meet the globalization, time-to-market and operational efficiency objectives of product development. Using the company’s CAD and content and process management solutions, organizations in the Industrial, High-Tech, Aerospace and Defense, Automotive, Consumer and Medical industries are able to support key business objectives and create innovative products that meet customer needs and comply with industry regulations. For more information on PTC, please visit http://www.ptc.com.
Except for the historical information contained herein, matters
discussed in this news release may constitute forward-looking statements
that involve risks and uncertainties that could cause actual results to
differ materially from those projected. These risks and uncertainties
include: PTC's successful continued development of the technologies
necessary to offer explicit modeling solutions as part of its evolving
product lifecycle management (PLM) solutions suite; the ability of PTC
to successfully partner and effectively coordinate and manage joint
activities (including development, marketing, implementation and
support) with third parties in order to efficiently and cost effectively
deliver multiple classes of PLM products and services that meet customer
requirements, the success of PTC’s customer satisfaction initiatives and
our ability to retain and maintain relationships with key employees,
distributors, customers and other strategic partners of CoCreate; and
our ability to effectively utilize our resources to support multiple PLM
product suites while maintaining recurring operations at satisfactory
levels to achieve our operating margin goals, together with such other
risks and uncertainties as are detailed from time to time in reports
filed by PTC with the Securities and Exchange Commission, including
PTC's most recent reports on Form 10-K and 10-Q. Information described
herein is furnished for informational use only, is subject to change
without notice, and should not be construed as a guarantee, commitment,
condition or offer by PTC. References to customer successes are based
upon a single user experience and such customer’s testimonial.